Last reviewed · How we verify
administration of Sinupret
administration of Sinupret is a Small molecule drug developed by Bionorica SE. It is currently in Phase 2 development.
At a glance
| Generic name | administration of Sinupret |
|---|---|
| Sponsor | Bionorica SE |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sinupret Extract Coated Tablets in Chronic Rhinosinusitis (PHASE3)
- Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC) (PHASE2)
- Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- administration of Sinupret CI brief — competitive landscape report
- administration of Sinupret updates RSS · CI watch RSS
- Bionorica SE portfolio CI
Frequently asked questions about administration of Sinupret
What is administration of Sinupret?
administration of Sinupret is a Small molecule drug developed by Bionorica SE.
Who makes administration of Sinupret?
administration of Sinupret is developed by Bionorica SE (see full Bionorica SE pipeline at /company/bionorica-se).
What development phase is administration of Sinupret in?
administration of Sinupret is in Phase 2.
Related
- Manufacturer: Bionorica SE — full pipeline
- Compare: administration of Sinupret vs similar drugs
- Pricing: administration of Sinupret cost, discount & access